Leflunomide Ab

Leflunomide, the active ingredient in Leflunomide Ab, is an immunomodulator presented as an oral tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients and belongs to the disease-modifying antirheumatic drug (DMARD) class.

GNH USA supplies Leflunomide Ab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable logistics for bulk and individual orders. Customers benefit from competitive pricing and comprehensive regulatory support.

Leflunomide is a disease-modifying antirheumatic drug used to manage inflammatory arthritis conditions.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriatic arthritis: improves skin lesions and joint symptoms. Inflammatory arthritis in adults: provides disease‑modifying effects to control systemic inflammation.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of sickness or urge to vomit. - Alopecia: thinning or loss of hair. - Rash: mild skin irritation or redness. - Elevated liver enzymes: increased ALT/AST levels. - Hypertension: rise in blood pressure.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury or failure. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Blood dyscrasias: neutropenia, anemia, or thrombocytopenia. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Before initiating therapy, clinicians should assess baseline health and monitor for potential risks.

Monitor liver function: perform baseline and periodic ALT/AST tests. Monitor blood pressure: check regularly, especially in hypertensive patients. Avoid in severe hepatic impairment: contraindicated when liver function is markedly reduced. Pregnancy and lactation: safety not established; use effective contraception. Drug interactions: review concomitant medications for CYP1A2 substrates. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Leflunomide can alter the activity of several co‑administered drugs.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Teriflunomide: additive toxicity, especially hepatic. - Methotrexate: heightened risk of liver injury. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise lef­unomide levels. - Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely): - Statins: possible increase in muscle toxicity. - Oral contraceptives: reduced efficacy, consider alternative methods. - Antihypertensives: potential alteration of blood pressure control. - Azathioprine: enhanced immunosuppression. - Rifampicin: may lower lef­unomide concentrations.